| Title: |
Valproate, carnitine metabolism, and biochemical indicators of liver function. |
| Authors: |
Beghi E; Bizzi A; Codegoni AM; Trevisan D; Torri W; Collaborative Group for the Study of Epilepsy; SPECCHIO, LUIGI MARIA |
| Contributors: |
Beghi, E; Bizzi, A; Codegoni, Am; Trevisan, D; Torri, W; Collaborative Group for the Study of, Epilepsy; Specchio, LUIGI MARIA |
| Publication Year: |
1990 |
| Collection: |
Università degli Studi di Foggia: CINECA IRIS Institutional Research Information System |
| Description: |
The effects of valproate (VPA) on carnitine and lipid metabolism and on liver function were assessed in 213 age- and sex-matched outpatients from five centers, with the following distribution: VPA monotherapy, 54; VPA polytherapy, 55; other monotherapies, 51; and untreated, 53. Mean total and free carnitine levels were significantly lower in patients with polytherapy; acylcarnitine was significantly higher for VPA monotherapy and the ratio of acyl- to free carnitine was significantly higher in all patients receiving VPA. Ammonia, uric acid, and bilirubin were the only tests selectively impaired with VPA. A significant correlation was found between serum ammonia and VPA dosage. Glucose, beta-lipoproteins, triglycerides, acetacetate, and beta-hydroxybutyrate were unchanged in the four groups. Sex and age appeared to interact with total and free carnitine values. Adverse drug reactions were apparently unrelated to carnitine metabolism impairment. Only a few patients had abnormal carnitine values. Our data support the assumption that carnitine deficiency and abnormal liver function due to VPA are mostly subclinical events. |
| Document Type: |
article in journal/newspaper |
| File Description: |
STAMPA |
| Language: |
English |
| Relation: |
volume:31; issue:3; firstpage:346; lastpage:352; numberofpages:7; journal:EPILEPSIA; https://hdl.handle.net/11369/227361 |
| Availability: |
https://hdl.handle.net/11369/227361 |
| Accession Number: |
edsbas.672DB9CA |
| Database: |
BASE |